Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | METAP2 | P50579 | 1/20 | 0.46 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21225851 | 0.83 | MCHR1 (0.45) | BDKRB2MCHR1 | |
| SCHEMBL7254011 | 0.80 | MCHR1 (0.36) | MEN1KMT2ACA12CA1CA9 | |
| SCHEMBL763980 | 0.79 | CCR1 (0.47) | MEN1KMT2AKDM4ELMNACA12 | |
| SCHEMBL9541397 | 0.79 | LMNA (0.49) | MEN1KMT2AKDM4ELMNAHTT | |
| SCHEMBL15398746 | 0.77 | MCHR1 (0.53) | MEN1KMT2AKDM4ELMNAHTT | |
| SCHEMBL15398749 | 0.77 | MCHR1 (0.53) | MEN1KMT2AKDM4ELMNAHTT | |
| SCHEMBL731812 | 0.76 | KMT2A (0.41) | MEN1KMT2AKDM4ELMNARAB9A | |
| SCHEMBL731813 | 0.76 | KMT2A (0.41) | MEN1KMT2AKDM4ELMNARAB9A | |
| SCHEMBL2349888 | 0.76 | CA1 (0.41) | MEN1KMT2AKDM4ELMNACA1 | |
| SCHEMBL873587 | 0.75 | MCHR1 (0.65) | MEN1KMT2AKDM4ELMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470208-B2 | Organometallic complexes | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-06-25 | — | — | US | disclosed |
| EP-1979437-B1 | ORGANOMETALLIC COMPLEXES | DU PONT (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20100264380-A1 | Organometallic complexes | E. I. DU PONT DE NEMOURS AND COMPANY | 2010-10-21 | — | — | US | disclosed |
| EP-1979437-A2 | ORGANOMETALLIC COMPLEXES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-10-15 | — | — | EP | disclosed |
| EP-0952832-B1 | QUINOLINE CARBOXAMIDES AS TNF INHIBITORS AND AS PDE-IV INHIBITORS | DARWIN DISCOVERY LTD (GB) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007087223-A2 | ORGANOMETALLIC COMPLEXES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-08-02 | — | — | WO | disclosed |
| US-6642254-B2 | Administering compounds, e.g., 8-methoxy-2-trifluoromethylquinoline-5-carboxylic acid (3,5-dichloro-1-oxypyridin-4-yl)amide for therapy of disease state that is capable of being modulated by inhibition of phosphodiesterase | DARWIN DISCOVERY, LTD. (GB) | 2003-11-04 | — | — | US | disclosed |
| US-20020183358-A1 | Heterocyclic compounds and their therapeutic use | DYKE HAZEL JOAN (GB) | 2002-12-05 | — | — | US | disclosed |
| US-6410559-B2 | 3,5-DISUBSTITUTED-(OXYPYRIDINE-4-YL)AMIDE DERIVATIVES USED AS PHOSPHODIESTERASE IV OR TUMOR NECROSIS FACTOR INHIBITOR TO TREAT INFLAMMATORY DISEASE OR AUTOIMMUNE DISEASE | DARWIN DISCOVERY, LTD. (GB) | 2002-06-25 | — | — | US | disclosed |
| US-20010025049-A1 | Heterocyclic compounds and their therapeutic use | DYKE HAZEL JOAN (GB) | 2001-09-27 | — | — | US | disclosed |
| US-6262070-B1 | E.G., 8-METHOXY-2-TRIFLUOROMETHYLQUINOLINE-5-CARBOXYLIC ACID(3,5-DICHLORO-1-OXYPYRIDIN-4-YL)AMIDE; TREATMENT OF CHRONIC OBSTRUCTIVE AIRWAYS DISEASE | DARWIN DISCOVERY LTD. (GB) | 2001-07-17 | — | — | US | disclosed |
| EP-1045845-A1 | N-OXIDES OF HETEROCYCLIC COMPOUNDS WITH TNF AND PDE-IV INHIBITING ACTIVITY | Darwin Discovery Limited (GB) | 2000-10-25 | — | — | EP | disclosed |
| WO-2000026208-A1 | N-OXIDES OF HETEROCYCLIC COMPOUNDS WITH TNF AND PDE-IV INHIBITING ACTIVITY | DARWIN DISCOVERY LIMITED (GB) | 2000-05-11 | — | — | WO | disclosed |
| US-5804588-A | TREATING DISEASES THAT ARE MODULATED BY INHIBITION OF PHOSPHODIESTERASE IV OR TUMOUR NECROSIS FACTOR | CHIROSCIENCE LIMITED (GB) | 1998-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025049-A1 | Heterocyclic compounds and their therapeutic use | CBR1, CBR3, CYC1 | MEN1 1624/4885KMT2A 4306/4885KDM4E 4615/4885 |
| US-20020183358-A1 | Heterocyclic compounds and their therapeutic use | CBR1, CBR3, CYC1 | MEN1 1624/4885KMT2A 4306/4885KDM4E 4615/4885 |
| US-20100264380-A1 | Organometallic complexes | GSTO1, CYP4F12, CYP4F3 | MEN1 3493/4885KMT2A 369/4885KDM4E 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.